Niagen Bioscience (NASDAQ:NAGE) Upgraded at Wall Street Zen

Niagen Bioscience (NASDAQ:NAGE) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report issued on Saturday.

A number of other research firms have also recently commented on NAGE. Weiss Ratings restated a “hold (c)” rating on shares of Niagen Bioscience in a report on Thursday, January 22nd. Canaccord Genuity Group dropped their price objective on shares of Niagen Bioscience from $14.00 to $13.00 and set a “buy” rating on the stock in a report on Thursday, March 5th. Three analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Niagen Bioscience Stock Performance

Niagen Bioscience stock opened at $4.20 on Friday. The stock has a market capitalization of $336.34 million, a price-to-earnings ratio of 21.00 and a beta of 2.11. Niagen Bioscience has a 52-week low of $4.20 and a 52-week high of $14.69. The stock’s 50 day moving average price is $5.22 and its two-hundred day moving average price is $6.61.

Hedge Funds Weigh In On Niagen Bioscience

A number of institutional investors have recently modified their holdings of the company. SG Americas Securities LLC grew its position in Niagen Bioscience by 5.7% in the 4th quarter. SG Americas Securities LLC now owns 54,649 shares of the company’s stock valued at $348,000 after purchasing an additional 2,950 shares during the period. Swiss National Bank increased its stake in Niagen Bioscience by 3.0% during the 4th quarter. Swiss National Bank now owns 110,100 shares of the company’s stock valued at $700,000 after purchasing an additional 3,200 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Niagen Bioscience by 5.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 60,342 shares of the company’s stock worth $384,000 after buying an additional 3,215 shares during the last quarter. Financial Consulate Inc. acquired a new position in Niagen Bioscience during the third quarter worth $33,000. Finally, Wells Fargo & Company MN lifted its stake in shares of Niagen Bioscience by 6.9% in the fourth quarter. Wells Fargo & Company MN now owns 58,337 shares of the company’s stock valued at $371,000 after buying an additional 3,740 shares in the last quarter. 15.41% of the stock is owned by institutional investors and hedge funds.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.